Early BBB breakdown and subacute inflammasome activation and pyroptosis as a result of cerebral venous thrombosis

• Published in: Brain research 2018-11, Vol.1699, p.54-68
• Main Authors: Rashad, Sherif, Niizuma, Kuniyasu, Sato-Maeda, Mika, Fujimura, Miki, Mansour, Ahmed, Endo, Hidenori, Ikawa, Shuntaro, Tominaga, Teiji
• Format: Article
• Language: English
• Subjects: Blood-brain barrier; Cerebral venous thrombosis; MMP9; Neuroinflammation; NLRP3; Sinus thrombosis
• ISSN: 0006-8993; 1872-6240
• DOI: 10.1016/j.brainres.2018.06.029

[Display omitted] •Superior sagittal sinus occlusion in rats induces subacute venous infarction.•Cerebral venous thrombosis (CVT) causes MMP9 mediated BBB breakdown.•CVT induces neuroinflammation and microglia activation.•CVT causes NLRP3 inflammasome activation and caspase-1 mediated cell death. Cerebral venous thrombosis (CVT) is a rare form of cerebral stroke that causes a variety of symptoms, ranging from mild headache to severe morbidity or death in the more severe forms. The use of anti-coagulant or thrombolytic agents is the classical treatment for CVT. However, the development of new therapies for the treatment of the condition has not been the focus. In this study, we aimed to analyze the pathophysiology of CVT and to identify the pathways associated with its pathology. Moreover, mechanisms that are potential drug targets were identified. Our data showed the intense activation of immune cells, particularly the microglia, along with the increase in macrophage activity and NLRP3 inflammasome activation that is indicated by NLRP3, IL-1β, and IL-18 gene and caspase-1 upregulation and cleavage as well as pyroptotic cell death. Leukocytes were observed in the brain parenchyma, indicating a role in CVT-induced inflammation. In addition, astrocytes were activated, and they induced glial scar leading to parenchymal contraction during the subacute stage and tissue loss. MMP9 was responsible primarily for the BBB breakdown after CVT and it is mainly produced by pericytes. MMP9 activation was observed before inflammatory changes, indicating that BBB breakdown is the initial driver of the pathology of CVT. These results show an inflammation driven pathophysiology of CVT that follows MMP9-mediated BBB breakdown, and identified several targets that can be targeted by pharmaceutical agents to improve the neuroinflammation that follows CVT, such as MMP9, NLRP3, and IL-1β. Some of these pharmaceutical agents are already in clinical practice or under clinical trials indicating a good potential for translating this work into patient care.